Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo. The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same o

Trial Details

NCT ID
NCT07288177
Phase
PHASE2
Sponsor
Genmab
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Rina-S
Locations (sample)
  • Fountain Valley, California, United States|33.70918,-117.95367
  • Santa Rosa, California, United States|38.44047,-122.71443
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Tampa, Florida, United States|27.94752,-82.45843
  • Lincoln, Nebraska, United States|40.8,-96.66696

Key Eligibility Criteria

  • Participant has histologically or cytologically confirmed metastatic or locally advanced NSCLC of adenocarcinoma histology, not amenable to curativ…
  • Participant must have radiological disease progression while on or after receiving the most recent regimen.
  • Participants either may have actionable genetic alterations (AGAs) or no AGAs.
  • Participant has measurable disease according to RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →